BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 2018;45:2426-41. [PMID: 29785514 DOI: 10.1007/s00259-018-4044-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer 2021;28:R81-93. [PMID: 33608483 DOI: 10.1530/ERC-20-0360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sgouros G, Frey E, Du Y, Hobbs R, Bolch W. Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. Eur J Nucl Med Mol Imaging 2021. [PMID: 34782911 DOI: 10.1007/s00259-021-05583-x] [Reference Citation Analysis]
3 Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends in Endocrinology & Metabolism 2020;31:239-55. [DOI: 10.1016/j.tem.2019.11.003] [Reference Citation Analysis]
4 Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 2020;19:589-608. [PMID: 32728208 DOI: 10.1038/s41573-020-0073-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 27.5] [Reference Citation Analysis]
5 St James S, Bednarz B, Benedict S, Buchsbaum JC, Dewaraja Y, Frey E, Hobbs R, Grudzinski J, Roncali E, Sgouros G, Capala J, Xiao Y. Current Status of Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys 2021;109:891-901. [PMID: 32805300 DOI: 10.1016/j.ijrobp.2020.08.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Jiménez-Mancilla N, Isaac-Olivé K, Torres-García E, Camacho-López M, Ramírez-Nava G, Mendoza-Nava H. Theoretical and experimental characterization of emission and transmission spectra of Cerenkov radiation generated by 177Lu in tissue. J Biomed Opt 2019;24:1-10. [PMID: 31313539 DOI: 10.1117/1.JBO.24.7.076002] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Walrand S, Bakhtina K. Direct effect of the Directive Euratom 2013/59 on European hospitals hosting radionuclide therapies. Phys Med 2022;96:121-2. [PMID: 35278929 DOI: 10.1016/j.ejmp.2022.03.004] [Reference Citation Analysis]
8 Di Stasio GD, Buonomano P, Travaini LL, Grana CM, Mansi L. From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model. Cancers (Basel) 2021;13:3474. [PMID: 34298688 DOI: 10.3390/cancers13143474] [Reference Citation Analysis]
9 Pizzoferro M, Cassano B, Altini C, Cacchione A, Cefalo MG, Cannatà V, Garganese MC. Imaging post-177Lu-peptide receptor radionuclide therapy in a child with advanced progressive somatostatin-receptor-positive medulloblastoma. Eur J Nucl Med Mol Imaging 2021;48:937-9. [PMID: 32767090 DOI: 10.1007/s00259-020-04966-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Huizing DMV, de Wit-van der Veen BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res 2018;8:89. [PMID: 30159614 DOI: 10.1186/s13550-018-0443-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
11 de Vries-Huizing DMV, Versleijen MWJ, Sinaasappel M, Walraven I, Geluk-Jonker MM, Tesselaar MET, Hendrikx JJMA, de Wit-van der Veen BJ, Stokkel MPM. Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course. PLoS One 2021;16:e0260073. [PMID: 34793530 DOI: 10.1371/journal.pone.0260073] [Reference Citation Analysis]
12 Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019;46:2536-44. [PMID: 31440799 DOI: 10.1007/s00259-019-04485-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 67] [Article Influence: 30.3] [Reference Citation Analysis]
13 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
14 Guedj E, Graillon T, Chinot O, Taieb D. Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:537-8. [PMID: 30552446 DOI: 10.1007/s00259-018-4221-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
15 Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05727-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kristiansson A, Örbom A, Vilhelmsson Timmermand O, Ahlstedt J, Strand SE, Åkerström B. Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. Antioxidants (Basel) 2021;10:1271. [PMID: 34439519 DOI: 10.3390/antiox10081271] [Reference Citation Analysis]
17 Lawhn-heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. The Lancet Oncology 2022;23:e75-87. [DOI: 10.1016/s1470-2045(21)00657-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer 2019;26:R627-52. [PMID: 31561209 DOI: 10.1530/ERC-19-0165] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 12.5] [Reference Citation Analysis]
19 Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, Gjertsson P, Bernhardt P. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med 2019;60:1406-13. [PMID: 30902877 DOI: 10.2967/jnumed.118.225235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
20 Inubushi M, Shidahara M, Takahashi Y, Ogawa M, Kiyono Y. From the respective expert viewpoints of the ANM specialty editors. Ann Nucl Med 2019;33:877-80. [PMID: 31745811 DOI: 10.1007/s12149-019-01421-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends Endocrinol Metab 2020;31:239-55. [PMID: 31839442 DOI: 10.1016/j.tem.2019.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Fisher DR. Perspectives on Internal Dosimetry for Optimized Radionuclide Therapy. Cancer Biother Radiopharm 2021. [PMID: 34569812 DOI: 10.1089/cbr.2021.0318] [Reference Citation Analysis]
23 Peer-Firozjaei M, Tajik-Mansoury MA, Geramifar P, Parach AA, Zarifi S. Implementation of dose point kernel (DPK) for dose optimization of 177Lu/90Y cocktail radionuclides in internal dosimetry. Appl Radiat Isot 2021;173:109673. [PMID: 33812266 DOI: 10.1016/j.apradiso.2021.109673] [Reference Citation Analysis]
24 Alevroudis E, Spei ME, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K. Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1813. [PMID: 33920195 DOI: 10.3390/cancers13081813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Widjaja L, Derlin T, Ross TL, Bengel FM, Werner RA. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy. Prostate 2022;82:86-96. [PMID: 34633090 DOI: 10.1002/pros.24250] [Reference Citation Analysis]
26 Roth D, Gustafsson J, Sundlöv A, Sjögreen Gleisner K. A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation. Med Phys 2018;45:5004-18. [PMID: 30199102 DOI: 10.1002/mp.13178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
27 Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics 2022;12:232-59. [PMID: 34987643 DOI: 10.7150/thno.62851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 O'neill E, Cornelissen B. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. Clin Cancer Res 2019;25:6939-47. [PMID: 31439583 DOI: 10.1158/1078-0432.CCR-19-1026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
30 Ritt P, Jobic C, Beck M, Schmidkonz C, Kuwert T, Uder M, Brand M. Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy. J Nucl Med 2021;62:379-85. [PMID: 32737244 DOI: 10.2967/jnumed.120.243782] [Reference Citation Analysis]
31 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
32 Barna S, Haug AR, Hartenbach M, Rasul S, Grubmüller B, Kramer G, Blaickner M. Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Clin Nucl Med 2020;45:661-7. [PMID: 32604113 DOI: 10.1097/RLU.0000000000003157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Siebinga H, de Wit-van der Veen BJ, Beijnen JH, Stokkel MPM, Dorlo TPC, Huitema ADR, Hendrikx JJMA. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. EJNMMI Res 2021;11:73. [PMID: 34398356 DOI: 10.1186/s13550-021-00821-7] [Reference Citation Analysis]
34 Kunikowska J, Zemczak A, Kołodziej M, Gut P, Łoń I, Pawlak D, Mikołajczak R, Kamiński G, Ruchała M, Kos-Kudła B, Królicki L. Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging 2020;47:922-33. [PMID: 31980909 DOI: 10.1007/s00259-020-04690-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
35 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Reference Citation Analysis]
37 Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology 2021;298:261-74. [PMID: 33231532 DOI: 10.1148/radiol.2020201745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Sundlöv A, Sjögreen-Gleisner K. Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment. Clin Oncol (R Coll Radiol) 2021;33:92-7. [PMID: 33189510 DOI: 10.1016/j.clon.2020.10.020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med 2019;60:377-85. [PMID: 30115686 DOI: 10.2967/jnumed.118.215848] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
40 Rydén T, Van Essen M, Marin I, Svensson J, Bernhardt P. Deep-Learning Generation of Synthetic Intermediate Projections Improves 177Lu SPECT Images Reconstructed with Sparsely Acquired Projections. J Nucl Med 2021;62:528-35. [PMID: 32859710 DOI: 10.2967/jnumed.120.245548] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Murray I, Flux G. Applying radiobiology to clinical molecular radiotherapy. Nucl Med Biol 2021;100-101:1-3. [PMID: 34091132 DOI: 10.1016/j.nucmedbio.2021.05.005] [Reference Citation Analysis]
42 Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35451612 DOI: 10.1007/s00259-022-05786-w] [Reference Citation Analysis]
43 Cicone F, Gnesin S, Cremonesi M. Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization. Q J Nucl Med Mol Imaging 2021;65:327-32. [PMID: 34881850 DOI: 10.23736/S1824-4785.21.03418-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Pouget JP, Santoro L, Piron B, Paillas S, Ladjohounlou R, Pichard A, Poty S, Deshayes E, Constanzo J, Bardiès M. From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience. Nucl Med Biol 2021;104-105:53-64. [PMID: 34922279 DOI: 10.1016/j.nucmedbio.2021.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
45 Chiesa C, Strigari L, Pacilio M, Richetta E, Cannatà V, Stasi M, Marzola MC, Schillaci O, Bagni O, Maccauro M. Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). Phys Med 2021;89:317-26. [PMID: 34583307 DOI: 10.1016/j.ejmp.2021.07.001] [Reference Citation Analysis]